Search Results - "Hoimes, C."

A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC) by Hoimes, C.J., Albany, C., Hoffman-Censits, J., Fleming, M.T., Trabulsi, E., Picus, J., Cary, C., Koch, M.O., Walling, R., Kelly, W., Godwin, J.L., Cooney, M., Fu, P., Nelson, A., Patel, K., Eitman, C., Breen, T., Neal, A., Kaimakliotis, H.

Get full text

Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy by Long, G.V., Milhem, M., Amin, A., Hoimes, C.J., Medina, T., Conry, R.M., Lao, C., Daniels, G., Reddy, S., Mehmi, I., Andtbacka, R.H.I., Barve, M., Shaheen, M., Tueting, T., Chisamore, M., Xing, B., Candia, A., Gamelin, E., Janssen, R., Ribas, A.

Get full text

Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy by Ribas, A., Mehmi, I., Medina, T., Lao, C., Kummar, S., Amin, A., Deva, S., Salama, A.K., Tueting, T., Milhem, M., Hoimes, C.J., Daniels, G., Shaheen, M., Jang, S., Barve, M., Powell, A., Chandra, S., Schmidt, E.V., Janssen, R., Long, G.V.

Get full text

Phase II California Cancer Consortium trial of gemcitabine–eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038) by Sadeghi, S, Groshen, S, Parikh, R, Mortazavi, A, Dorff, T, Hoimes, C, Pal, S, Levine, E, Doyle, L, Quinn, D, Newman, E, Lara, P

Get full text

PCR53 Patient Experiences Before and After Enfortumab Vedotin Neoadjuvant Treatment in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer by Flaig, T, Hepp, Z, Narayanan, S, Whyte, J, Johnson, N, Matsuda, T, Hoimes, C

Get full text

500LBA LBA Orals: Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301) by Tran, B., Boni, A., Hansen, A., Boni, V., Mantia, C., Yu, E., Weickhardt, A., Robert, M., Gupta, S., Necchi, A., Morales-Barrera, R., Hoimes, C., Berlin, J., Iyer, G., Millward, M., Burn, T., Lihou, C., Gammon, G., Rosenberg, J., Loriot, Y.

Get full text

35 (PB023): A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301) by Zhang, A., Boni, V., Hanson, A., Mantia, C., Weickhardt, A., Yu, E., Gupta, S., Robert, M., Iyer, G., Millward, M., Morales-Barrera, R., Hoimes, C., Berlin, J., Mittal, K., Hill, A., Racca, F., Pouessel, D., Lihou, C., Tran, B., Loriot, Y.

Get full text

988TiPKEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC) by Siefker-Radtke, A O, Steinberg, G, Bedke, J, Nishiyama, H, Martin, J, Kataria, R, Frenkl, T L, Hoimes, C J

“…Abstract Background MIBC is associated with a high rate of recurrence and poor overall prognosis despite aggressive local and systemic therapy. With standard…”
Get full text

61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199 by Graff, J.N., Tagawa, S., Hoimes, C., Gerritsen, W., Vaishampayan, U.N., Elliott, T., Hwang, C., Tije, A.J. Ten, Omlin, A.G., McDermott, R.S., De Wit, R., Qiu, P., Poehlein, C., Kim, J., Suttner, L., Cristescu, R., Marton, M.J., Schloss, C., de Bono, J.S., Antonarakis, E.S.

Get full text

Phase II California cancer consortium trial of gemcitabine-eribulin combination (ge) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): Efficacy report (NCI-9653; 1UM1CA186717, NO1-CM-2011-00038) by Sadeghi, S., Groshen, S., Parikh, R.A., Mortazavi, A., Dorff, T., Hoimes, C., Doyle, L., Quinn, D.I., Newman, E., Lara, P.

Get full text

901OEV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma by Hoimes, C J, Rosenberg, J E, Srinivas, S, Petrylak, D P, Milowsky, M, Merchan, J R, Bilen, M A, Gupta, S, Carret, A-S, Yuan, N, Melhem-Bertrandt, A, Flaig, T

“…Abstract Background Platinum-based chemotherapy remains the standard of care for patients (pts) with locally advanced or metastatic urothelial carcinoma…”
Get full text

Avelumab in patients with metastatic adrenocortical carcinoma (mACC): Results from the JAVELIN solid tumor trial by Le Tourneau, C., Zarwan, C., Hoimes, C., Wong, D.J., Bauer, S., Wermke, M., Grote, H.J., von Heydebreck, A., Chin, K., Gulley, J.

Get full text

2198 - Phase II California Cancer Consortium trial of gemcitabine–eribulin combination (GE) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): tolerability and toxicity report (NCI-9653; 1UM1CA186717-01, NO1-CM-2011-00038) by Sadeghi, S., Groshen, S., Parikh, R., Mortazavi, A., Dorff, T., Hoimes, C., Pal, S., Levine, E., Doyle, L., Quinn, D., Newman, E., Lara, P.

Get full text

A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC) by Beltran, H., Danila, D., Montgomery, B., Szmulewitz, R., Vaishampayan, U., Armstrong, A., Stein, M., Hoimes, C., Pinski, J., Scher, H., Puca, L., Bareja, R., Wong, W., Rubin, M., Mosquera, J.M., Sboner, A., Oromendia, C., Nanus, D., Ballman, K., Tagawa, S.T.

Get full text

Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status by Mirsky, Matthew M, Mitchell, Carley, Hong, Augustine, Cao, Shufen, Fu, Pingfu, Margevicius, Seunghee, Wu, Sulin, Dowlati, Afshin, Nelson, Ariel, Selfridge, J. Eva, Ramaiya, Nikhil, Hoimes, Christopher, Alahmadi, Asrar, Bruno, Debora S

“…Purpose: Disparities in cancer care delivery remain a pressing health-care crisis within the United States (US). The use of immune checkpoint inhibitors (ICIs)…”
Get full text

LBA33A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC) by Hoimes, C J, Albany, C, Hoffman-Censits, J, Fleming, M T, Trabulsi, E, Picus, J, Cary, C, Koch, M O, Walling, R, Kelly, W, Godwin, J L, Cooney, M, Fu, P, Nelson, A, Patel, K, Eitman, C, Breen, T, Neal, A, Kaimakliotis, H

Get full text

LBA45Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy by Long, G V, Milhem, M, Amin, A, Hoimes, C J, Medina, T, Conry, R M, Lao, C, Daniels, G, Reddy, S, Mehmi, I, Andtbacka, R H I, Barve, M, Shaheen, M, Tueting, T, Chisamore, M, Xing, B, Candia, A, Gamelin, E, Janssen, R, Ribas, A

Get full text

1265PPhase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy by Ribas, A, Mehmi, I, Medina, T, Lao, C, Kummar, S, Amin, A, Deva, S, Salama, A K, Tueting, T, Milhem, M, Hoimes, C J, Daniels, G, Shaheen, M, Jang, S, Barve, M, Powell, A, Chandra, S, Schmidt, E V, Janssen, R, Long, G V

Get full text

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study by Antonarakis, Emmanuel S, Piulats, Josep M, Gross-Goupil, Marine, Goh, Jeffrey, Ojamaa, Kristiina, Hoimes, Christopher J, Vaishampayan, Ulka, Berger, Ranaan, Sezer, Ahmet, Alanko, Tuomo, de Wit, Ronald, Li, Chunde, Omlin, Aurelius, Procopio, Giuseppe, Fukasawa, Satoshi, Tabata, Ken-Ichi, Park, Se Hoon, Feyerabend, Susan, Drake, Charles G, Wu, Haiyan, Qiu, Ping, Kim, Jeri, Poehlein, Christian, de Bono, Johann Sebastian

“…Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)-positive metastatic castration-resistant prostate cancer…”
Get full text

A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome by Mehnert, J. M., Mortazavi, A., Stein, M. N., Donadio, A. C., Zelterman, D., McDonough, J. A., Rowen, E., Hoimes, C. J., Gibney, G., Kelly, W. K.

“…Abstract only 278 Background: Sorafenib is an oral tyrosine kinase inhibitor with anti-angiogenic properties that may enhance the antitumor activity of GC and…”
Get full text